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Background: Prostate tumor overexpressed 1 (PTOV1) was demonstrated to play an important role in cancer
progression and was correlated with unfavorable clinical outcome. However, the clinical role of PTOV1 in cancer
remains largely unknown. This study aimed to investigate the expression and clinicopathological significance of
PTOV1 in breast cancer.
Methods: The mRNA and protein expression levels of PTOV1 were analyzed in 12 breast cancer cell lines and
eight paired breast cancer tumors by semi-quantitative real time-PCR and western blotting, respectively.
Immunohistochemistry was performed to assess PTOV1 protein expression in 169 paraffin-embedded, archived
breast cancer samples. Survival analysis and Cox regression analysis were performed to investigate the
clinicopathological significance of PTOV1 expression.
Results: Our data revealed that PTOV1 was frequently overexpressed in breast cancer cell lines compared to normal
human breast epithelial cells and in primary breast cancer samples compared to adjacent noncancerous breast
tissues, at both the mRNA and protein levels. Moreover, high expression of PTOV1 in breast cancer is strongly
associated with clinicopathological characteristics and estrogen receptor expression status (P = 0.003). Breast cancer
patients with higher PTOV1 expression had substantially shorter survival times than patients with lower PTOV1
expression (P < 0.001). Univariate and multivariate analysis revealed that PTOV1 might be an independent
prognostic factor for breast cancer patients (P = 0.005).
Conclusions: Our study showed that PTOV1 is upregulated in breast cancer cell lines and clinical samples, and its
expression was positively associated with progression and aggressiveness of breast cancer, suggesting that PTOV1
could serve as an independent prognostic marker.
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Human breast cancer is the most common carcinoma in
females, and the second leading cause of cancer related
mortality in women, accounting for approximately 29%
(232,340) of all new cancer cases among women and 14%
(39,620) cancer related mortality, representing a serious* Correspondence: lify@sysyucc.org.cn; liujl@sysucc.org.cn
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unless otherwise stated.health threat to women worldwide [1,2]. Although various
treatments for breast cancer, such as chemotherapy, radi-
ation and hormone therapy, have been used and have
been improved recently, the clinical outcome of pa-
tients remains unsatisfactory. This is largely because of a
lack of effective and specific biomarkers that predict breast
cancer. Thus, it is important to identify new genes and
molecules that can effectively distinguish patients with fa-
vorable prognosis from those with poor prognosis, and to
develop new therapy options for breast cancer patients.
Prostate tumor overexpressed 1 (PTOV1), a 46 kDa
protein with two repeated PTOV homology blocks, was
first identified during a screen for genes overexpressedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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region of chromosome 19 (19q13) that is associated with
high risk of breast cancer [4,5]. PTOV1 comprises 12
exons, and the encoded protein has two almost identical
tandemly arranged PTOV domains, each containing a po-
tential nuclear localization signal [3]. PTOV1 expression
is elevated in multiple cancers, including lung, endomet-
rium, bladder, kidney and ovary cancer [6]. However, the
expression and clinical relevance of PTOV1 in breast can-
cer have not been determined. Additionally, PTOV1 was
reported to be associated with tumor development and
progression. Recently, PTOV1 was shown to force cells to
enter S phase and to promote mitotic activity of prostate
cancer cells. High levels of PTOV1 expression are signifi-
cantly associated with Ki67 immunostaining, indicating
that PTOV1 upregulation is functionally related to prolif-
erative status [7,8]. PTOV1 negatively regulates retinoic
acid receptor transcription activity by antagonizing medi-
ator complex subunit 25 [9]. Marqués N et al. reported
that PTOV1 promotes c-Jun expression at the post-
transcriptional level, which enhanced the invasive and
metastatic capacity of prostate cancer cells [10]. Accumu-
lating data indicate that PTOV1 might play an essential
role in tumorigenesis.
In the present study, e aimed to investigate the expres-
sion of PTOV1 in breast cancer and its relationship with
clinical parameters and prognosis in breast cancer pa-
tients. The results showed that PTOV1 is significantly
upregulated in breast cancer, and overexpression of
PTOV1 is closely associated with the clinical stage, T, N
and M classification, and estrogen receptor (ER) expression
levels in breast cancer. Cox regression analysis revealed
that PTOV1 might be considered as an independent bio-
marker for breast cancer prognosis. Collectively, our find-
ings strongly suggested that PTOV1 plays an important
role in the development and progression of human breast
cancer, and might be a useful predictive marker of progno-
sis in breast cancer patients.
Methods
Cell lines
Primary normal breast epithelial cells (NBEC) were
established according to a previous report [11]. Immor-
talized breast epithelial cells MCF-01A were maintained
in keratinocyte serum-free medium and breast cancer
cell lines, including BT474, BT549, MDA-MB-435,
MDA-MB-453, MDA-MB-231, MDA-MB-415, MDA-
MB-468, T47D, MCF-7, ZR-75-1, ZR-75-30, SKBR-3,
and Bcap-37 were purchased from ATCC and main-
tained in DMEM medium (Invitrogen) supplemented
with 10% fetal bovine serum (HyClone, Logan, UT,
USA) and 100 μg/ml penicillin, and 100 μg/ml strepto-
mycin (Invitrogen) at 37°C in a humidified atmosphere
containing 5% CO2.Tissue specimens and patient information
A total of 169 breast cancer paraffin-embedded speci-
mens from female patients, which had been histopatho-
logically and clinically diagnosed as breast cancer at the
Cancer Center, Sun Yat-sen University from 2003 to 2007,
were used in the present study. Tumor grade and stage
were defined according to the 6th edition of the TNM
classification of the Union for International Cancer
Control (UICC, 2002). For the use of these clinical materials
for research purposes, prior patients’ consents and approval
from Sun Yat-sen University Cancer Center Institutional
Review Board were obtained. Clinical information on the
samples is summarized in Table 1. The median age at the
time of surgery was 47 years (range 22–96 years). The
follow-up time of the primary breast cancer cohort ranged
from 9 to 115 months, and the median follow-up time
was 59 months. The percentage of tumor purity in sec-
tions adjacent to the regions used for RNA extraction was
estimated during routine histopathological analysis.
RNA extraction, reverse transcription and real-time PCR
Total RNA from cells and fresh surgically obtained
tumor tissues and their adjacent noncancerous tissues was
extracted using the Trizol reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instruction. The ex-
tracted RNA was pretreated with RNase-free DNase, and
2 μg of RNA from each sample was used for cDNA
synthesis primed with random hexamers. For PCR ampli-
fication of PTOV1 cDNA, an initial amplification using
PTOV1 specific primers was done with a denaturation
step at 95°C for 10 min, followed by 28 cycles of denatur-
ation at 95°C for 60 s, primer annealing at 58°C for 30 s,
and primer extension at 72°C for 30 s. Upon completion
of the cycling steps, a final extension at 72°C for 5 minutes
was done before the reaction was stored at 4°C. Real-time
PCR was applied to measure the fold of increase of
PTOV1 mRNA in each of the primary breast tumors rela-
tive to the paired normal breast tissue obtained from the
same patient. Real-time PCR primers were designed using
the Primer Express v 2.0 software (Applied Biosystems).
The sequences of real-time PCR primers were: PTOV1
Forward: CGAGTACAGGAGCATGAGCA and Reverse:
CTTCACCAACAGAGACTGCG; GAPDH Forward: GA
CTCATGACCACGTCCATGC and Reverse: AGAGGC
AGGGATGATGTTCTG. Expression data were nor-
malized to the geometric mean of housekeeping gene
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
to control the variability in expression levels and analyzed
using the 2-△△Ct method described by the previous report
[12], and all experiments were performed in triplicate.
Western blotting
Cells were washed twice with ice-cold phosphate-buffered
saline (PBS), then lysed on ice in radioimmune-precipitation
Table 1 Clinicopathological characteristics of
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fer containing complete protease inhibitor cocktail (Roche
Applied Sciences, Mannheim, Germany) and heated for
5 min at 100°C. Fresh tissue samples were ground to pow-
der in liquid nitrogen and lysed with SDS-PAGE sample
buffer. Equal protein samples (30 μg) were separated on
10.5% SDS polyacrylamide gels and transferred to PVDF
membranes (Immobilon P, Millipore, Bedford, MA).
Membranes were blocked with 5% fat-free milk in
Tris-buffered saline containing 0.1% Tween-20 (TBST)
for 1 h at room temperature. Membranes were incubated
with anti-PTOV1 antibody (1:100, Sigma, HPA051812)
overnight at 4°C, and then with horseradish peroxidase-
conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology,
SC-2004). To evaluate PTOV1 expression, enhanced
chemiluminescence system (ECL) prime Western blot-
ting detection reagent (Amersham) were used according
to the manufacturer’s instructions. α-Tubulin (Sigma,
Saint Louis, MO) was used as a loading control.
Immunohistochemistry analysis
Immunohistochemical analysis was done to measure PTOV1
protein expression in 169 human breast cancer tissues.
Briefly, paraffin embedded specimens were cut into 4 μm
sections and baked at 60°C for 2 hours, followed by depar-
affinized with xylenes and rehydrated. Antigenic retrieval
was done by submerging the Sections into EDTA anti-
genic retrieval buffer and microwaving. The sections were
then treated with 3% hydrogen peroxide in methanol to
quench the endogenous peroxidase activity, followed by
incubation with 1% bovine serum albumin to block
the nonspecific binding. Sections were then incubated
with anti-PTOV1 rabbit polyclonal antibody (1:50, Sigma,
HPA051812) overnight at 4°C. For negative controls, the
primary antibody was replaced by normal goat serum.
After washing, the tissue sections were treated with bio-
tinylated anti-rabbit secondary antibody (Abcam), followed
by a further incubation with streptavidin-horseradish
peroxidase complex (Abcam). The tissue sections were
immersed in 3-amino-9-ethyl carbazole and counterstained
with 10% Mayer’s hematoxylin, dehydrated and mounted
in Crystal Mount.
The degree of immunostaining of the sections was viewed
and scored separately by two independent investigators,
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tient data of the samples. The scores were determined by
combining the proportion of positively stained tumor cells
and the intensity of staining. Scores given by the two inde-
pendent investigators were averaged for further compara-
tive evaluation of the PTOV1 expression. The proportion
of positively stained tumor cells was graded as follows: 1
(< 10% positive tumor cells), 2 (10-50% positive tumor
cells), 3 (50-75% positive tumor cells), and 4 (> 75% posi-
tive tumor cells). The intensity of staining was recorded as
following: 0 (no staining), 1 (weak staining, light yellow),
2 (moderate staining, yellowish brown), and 3 (strong
staining, brown). The staining index was calculated as
the product of the proportion of positive cells and the
staining intensity score. Cutoff values to define the high
and low expression of PTOV1 were chosen based on a
measure of heterogeneity with the log-rank test statistics
with respect to overall survival (OS). An optimal cut-off
value was identified: a staining index score of greater or
equal to 6 was used to define tumors with high PTOV1
expression and a score less than or equal to 4 indicated
low PTOV1 expression.
Statistical analysis
All statistical analyzes were carried out using the SPSS
16.0 statistical software packages. The chi-square test
and Fisher’s exact test were used to analyze the correl-
ation between PTOV1 expression and the clinicopatho-
logic characteristics. Bivariate correlations between study
variables were calculated by Spearman’s rank correl-
ation coefficients. Survival curves were plotted using the
Kaplan-Meier method and compared with the log-rank
test. The significance of various variables for survival was
analyzed by univariate and multivariate Cox regression
analyzes. All reported P-values are two-sided. A P-value
of less than 0.05 was considered statistically significant in
all cases.
Results
PTOV1 is upregulated in breast cancer cell lines
To explore the potential role of PTOV1 in the tumori-
genesis of breast cancer, the expression of the PTOV1
protein and mRNA were determined by western blotting
and real time-PCR. Higher PTOV1 protein expression
was observed in all 12 breast cancer cell lines compared
with that in two primary cultured normal human mam-
mary epithelial cells (NMEC), in which it was weakly de-
tected (Figure 1A). In line with the finding of protein
expression, the mRNA expression of PTOV1 was signifi-
cantly higher in breast cancer cell lines than in NMEC
(Figure 1B). These results indicated that PTOV1 is up-
regulated in breast cancer cell lines. Since the cell lines
we tested vary in ER status, PR status, HER2 status, mu-
tant p53 status, and they belong to either luminal orbasal-like type, we summarized these statuses and ana-
lyzed the correlation between PTOV1expression and
these statuses (Additional file 1: Table S1). Briefly, we de-
fine the high or low PTOV1 expression by the median of
the density scan of Western blotting detection of the pro-
tein expression of the cell lines. The results showed that
there were no significant differences between PTOV1 ex-
pression and these features of the breast cancer cell lines.
This may due to that backgrounds of these cell lines we
used in the study are not well understood and these genes
express differently in cell lines and breast cancer tissues.
PTOV1 is overexpressed in breast cancer tissues and
associated with breast cancer progression
To determine whether PTOV1 is upregulated in breast
cancer tissues, four pairs of matched breast cancer tis-
sues and the noncancerous tissue adjacent to the malig-
nant lesion were used for the further examination. As
shown in Figure 2, PTOV1 was markedly upregulated at
both the protein and mRNA levels in all eight human pri-
mary breast cancer samples compared with the matched
adjacent noncancerous breast tissues. Differential expres-
sion, as measured by the T/ANT ratio of mRNA levels,
ranged between 10.2 fold to 17.8 fold. Consistent with the
above data, the expression of PTOV1 protein was elevated
at least 2.3-fold higher in cancer tissues compared with
their noncancerous counterparts. In summary, these data
suggested that PTOV1 is overexpressed in breast cancer
tissues.
To further explore whether PTOV1 upregulation is as-
sociated with clinicopathological characteristics of breast
cancer, we examined the PTOV1 expression status in
169 paraffin-embedded, archived breast cancer tissues by
immunohistochemistry (IHC). The archived tissue came
from 30 patients with stage I cancer, 81 patients at stage II,
53 patients at stage III, and five patients at stage IV. As
shown in Table 1, PTOV1 expression was detected in 167
of 169 (99.4%) cases. Among the PTOV1-positive cases, 83
(49.1%) cases had high levels of PTOV1 expression, while
86 (50.9%) cases had low levels of PTOV1 expression. High
PTOV1 expression was observed in areas containing pri-
mary breast cancer cells; however, it was undetectable or
only marginally detectable in normal breast tissues and ad-
jacent non-cancerous tissues (Figure 2). The subcellular
location of PTOV1 was mainly in the cytoplasm of pri-
mary cancer cells, which is consistent with previous
reports [8,12] (Figure 2). Furthermore, IHC revealed
that increasing PTOV1 staining was positively correlated
with advancing clinical stage and higher pathological
grade (Figure 3A). Quantitative IHC analysis revealed that
the median optical density (MOD) values of PTOV1 stain-
ing in all breast cancer were higher than that in control
normal tissues. In addition, the MOD values of PTOV1
significantly increased with progression of tumor grades
Figure 1 Overexpression of PTOV1 in breast cancer cell lines and normal human mammary epithelial cell lines. Expression of PTOV1
mRNA and protein in an immortalized “normal” breast epithelial cell line MCF-10A and breast cancer cell lines (MCF-7, ZR-75-1, MDA-MB-231,
MDA-MB-435, MDA-MB-453, ZR-75-30, MDA-MB-415, MDA-MB-468, BT549, BT474, SKBR3, Bcap37, T47D) and two normal human mammary epithelial
cell lines (NMEC1, NMEC2) were examined by western blotting (A) and real-time PCR (B). Expression levels were normalized for α−Tubulin and GAPDH,
respectively. Error bars represent SD from three independent experiments. *P < 0.05.
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results suggested that upregulation of PTOV1 is associ-
ated with breast cancer progression.
Statistical analysis was performed to evaluate the clin-
ical significance between the PTOV1 expression and the
clinicopathological parameters of breast cancer. As sum-
marized in Table 2, PTOV1 expression was strongly cor-
related with clinical stage (P = 0.005), T classification
(P = 0.048), N classification (P = 0.035), M classifica-
tion (P = 0.021) and estrogen receptor (ER) expression
levels (P = 0.003), but not significantly associated with
age, progesterone receptor (PR) expression levels and
c-erbB2 expression levels. Moreover, Spearman correl-
ation analysis suggested that the PTOV1 expression level
was markedly associated with clinical stage (r = 0.256, P =
0.001), T classification (r = 0.181, P = 0.018), N classifica-
tion (r = 0.224, P = 0.003), M classification (r = 0.178, P =
0.021) and ER expression levels (r = 0.246, P = 0.001)
(Table 3). Taken together, our data showed that overex-
pression of PTOV1 is positively correlated with clinicalstage; T, N, M classification; and ER expression levels, which
further supported the hypothesis that the elevated PTOV1
expression is associated with breast cancer progression.
PTOV1 expression level is associated with the patient
survival and prognosis
Assessment of patient survival by the Kaplan–Meier ana-
lysis indicated an adverse correlation between PTOV1 ex-
pression and overall survival time of patients with breast
cancer (P < 0.001) (Figure 4A). The 5-year cumulative sur-
vival rates of patients with higher PTOV1 expression and
lower PTOV1 expression were 66.3% and 91.6%, respect-
ively. The median survival time of patients with breast
cancer with low PTOV1 expression was 115 months,
compared with 78 months for patients with high PTOV1
expression.
Univariate and multivariate Cox proportional hazard re-
gression analysis were performed to identify the independ-
ent prognostic value of each variable for predicting overall
survival in patients. PTOV1 expression (P = 0.008) and
Figure 2 (See legend on next page.)
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Figure 2 Overexpression of PTOV1 in breast cancer tissues. Expression of PTOV1 protein and mRNA in eight pairs of breast tissues (T) and
matched adjacent non-cancerous tissues (ANT) from the same patient were determined by western blotting (A) and real-time PCR (B), respectively.
(C) Expression of PTOV1 protein in each of the primary breast cancer tissues and matched adjacent non-cancerous tissues examined by
immunohistochemistry. *P < 0.05.
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pN status (P = 0.001) and PR expression (P = 0.017), which
showed significant effects on overall survival by univariate
analysis, were included in multivariate analysis (Table 4).
As expected, PTOV1 was identified as an independent
prognostic factor for patients with poor survival (relative
risk: 1.230, 95% CI: 1.475-8.025, P = 0.005).Figure 3 PTOV1 protein overexpression in archived paraffin-embedded
(A) Representative IHC images of PTOV1 expression in normal human b
(B) Statistical analyses of the average MOD of PTOV1 staining between no
clinical stages. *P < 0.05.Moreover, the prognostic value of PTOV1 expression
was analyzed when stratifying the patients according to
different pT/pN/pM statuses and clinical stages. These
findings suggested that overexpression of PTOV1 was an
strong inverse prognostic factor for breast cancer patients
in clinical stage I–II (early stage, P = 0.026) and III–IV
(late stage, P = 0.001), indicating that PTOV1 could bebreast cancer tissue sections examined by immunohistochemistry.
reast tissues and breast cancer tissues of different clinical stages.
rmal human breast tissues and breast cancer specimens of different
Table 2 Clinicopathological characteristics of patient samples and expression of PTOV1 in breast cancer and
correlation between PTOV1 expression and clinicopathological characteristics of breast cancer patients
Characteristics Total PTOV1 chi-square
test P-value
Fisher’s exact
test P-valueLow expression (%) High expression (%)
Age (y) ≥ 47 82 43 (52.4) 39 (47.6) 0.695 0.406
< 47 87 43 (49.4) 44 (50.6)
Clinical stage I 30 20 (66.7) 10 (33.3) 0.005 0.003
II 81 46 (56.8) 35 (43.2)
III 53 20 (37.7) 33 (62.3)
IV 5 0 (0) 5 (100)
T classification T1 52 31 (59.6) 21 (40.4) 0.048 0.046
T2 88 46 (52.3) 42 (47.7)
T3 17 7 (41.2) 10 (58.8)
T4 12 2 (16.7) 10 (83.3)
N classification N0 72 45 (62.5) 27 (37.5) 0.035 0.036
N1 50 24 (48) 26 (52)
N2 30 12 (40) 18 (60)
N3 17 5 (29.4) 12 (70.6)
M classification Yes 5 0 (0.0) 5 (100.0) 0.021 0.027
No 164 86 (52.4) 78 (47.6)
Expression of ER 0 74 45 (60.8) 29 (39.2) 0.003 0.003
1 37 23 (62.2) 14 (37.8)
2 16 5 (31.3) 11 (68.5)
3 42 13 (31.0) 29 (69.0)
Expression of PR 0 75 42 (56.0) 33 (44.0) 0.092 0.093
1 28 15 (53.6) 13 (46.4)
2 27 16 (59.3) 11 (40.7)
3 39 13 (33.3) 26 (66.7)
Expression of HER 2 0 90 42 (46.7) 48 (53.3) 0.588 0.599
1 20 12 (60.0) 8 (40.0)
2 13 8 (61.5) 5 (38.5)
3 46 24 (62.5) 22 (37.5)
Vital status Live 131 78 (59.5) 53 (40.5) < 0.001 < 0.001
Dead 38 8 (21.1) 30 (78.9)
Table 3 Spearman correlation analysis between PTOV1
and clinical pathologic factors
Variables PTOV1 expression
Spearman correlation p-Value
Clinical staging 0.256 0.001
T classification 0.181 0.018
N classification 0.224 0.003
M classification 0.178 0.021
ER expression 0.246 0.001
PR expression 0.141 0.067
HER2 expression −0.069 0.372
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cancer in all disease stages (Figure 4B, C). Similarly,
patients with higher PTOV1 expression level had sig-
nificantly shorter survival time in groups of: pT1-2
(P < 0.001) (Figure 4D), lymph node metastasis positive
(including: pN1, pN2 and pN3) (P < 0.001) (Figure 4E)
and pM0 (P < 0.001) (Figure 4F). However, no statistically
significant differences were identified between PTOV1 ex-
pression and survival time in subsets of pT3-4, pN0 and
pM1, which might reflect the limited number of patients
recruited in each subset. Taken as a whole, these results
indicate that PTOV1 could be a useful prognostic factor
in breast cancer patients.
Figure 4 (See legend on next page.)
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Figure 4 Kaplan-Meier analysis of overall survival in breast patients based on PTOV1 expression. (A) OS of all patients with high PTOV1
expression versus low PTOV1 expression. (B) OS rate for patients with high PTOV1 expression versus patients with low PTOV1 expression
in patients with T1-T2 grade tumors. The overall survival of patients of high PTOV1 expression and low PTOV1 expression compared
between patients with early stage disease (stage I–II) (C) and late stage disease (stage III–IV) (D) and between patients with negative
metastasis disease (E) and between patients with positive lymph node metastasis (F). P values were calculated by using log-rank tests.
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In the present study, we provided the first evidence that
overexpression of PTOV1 protein is associated with
poor prognosis of breast cancer patients with both early-
and late-stage disease. Our data showed that PTOV1 is
upregulated in breast cancer cell lines and in clinical
tumor specimens, at both the mRNA and protein levels,
compared with normal breast epithelial cells and normal
breast tissues, respectively. Moreover, the analysis of 169
archived breast cancer samples revealed that PTOV1 ex-
pression is significantly associated with progression of
breast cancer; a high level of PTOV1 might correlate
with a shorter survival time (P < 0.001), indicating that
PTOV1 plays an important role in breast cancer pro-
gression. Furthermore, Cox regression analysis showed
that higher PTOV1 expression was an independent
prognostic indicator of shorter survival in breast cancer
patients. These findings strongly suggested that lower
expression of PTOV1 would provide a selective advan-
tage in prognosis for breast cancer patients.Table 4 Univariate and multivariate analyses of various progn
regression analysis
Variables Univariate analysis
No. patients p Regression coeffi
PTOV1 0.008 0.571 (0.20
Low expression 86
High expression 83














3 39PTOV1 was first identified as a novel elevated
expressed gene in prostate cancer [3]. Aberrant PTOV1
expression is associated with tumor progression in pros-
tate cancer and other neoplasms [3,6]. PTOV1 was re-
ported to assist Flotillin-1 nuclear translocation and
promote the mitogenic activity of Flotillin-1 in a cell
cycle-dependent manner [7]. Flotillin-1 promotes
tumorigenesis of various cancers, such as esophageal
squamous cell carcinoma, non-small cell lung cancer
and breast cancer [13-16]. Flotillin-1 promotes breast
cancer carcinogenesis inducing entry into the S phase of
the cell cycle and by upregulating the transcription fac-
tor Foxo3a [16]. Thus, we assumed that PTOV1 might
promote breast cancer progression through a similar
mechanism. Further investigations are required to test
this assumption. In quiescent cells, PTOV1 is mainly lo-
calized in the cytoplasm and is excluded from the nu-
cleus. However, elevated nuclear PTOV1 is closely
correlated with high Ki67 immunoreactivity, indicating
that PTOV1 plays an important role in cells proliferativeostic parameters in patients with breast cancer Cox-
Multivariate analysis
cient (SE) p Relative risk 95% confidence interval
6) 0.005 1.230 1.457-8.025
4) 0.003 0.507 1.181-2.327
3) <0.001 0.808 1.625-3.097
2) 0.012 0.340 1.079-1.820
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pressing PTOV1 showed an increased growth rate and
tumorigenic capacity [10]. Taken together, these results
confirmed that overexpression of PTOV1 could contrib-
ute to the proliferative status of tumor cells, indicating
that PTOV1 is involved in the progression of cancer.
Recently, PTOV1, which is a modulator of the medi-
ator transcriptional regulatory complex, was revealed to
regulate c-Jun expression at the posttranscriptional level
[10]. c-Jun is a major component of the AP-1 complex
and is associated with a variety of biological processes,
including proliferation and differentiation [17]. c-Jun is
thought to induce mammary cell invasiveness, which
plays an important role in breast cancer metastasis and
stem cell expansion [18]. Therefore, we speculated that
PTOV1 might promote breast cancer tumorigenesis
through the transcription factor c-Jun and its down-
stream genes. Furthermore, a previous study found that
high PTOV1 expression might be a good predictor of
prostate cancer in men with isolated high-grade pros-
tatic intraepithelial neoplasms in needle biopsies [19,20].
Thus, PTOV1 might be a positive regulator of breast
cancer development and progression; however, the exact
mechanism needs further investigation.
Breast cancer patients with the same clinical stage, which
is routinely classified by TNM stage system, often have dis-
tinct outcomes. This large difference indicates that the
TNM stage system alone is not sufficient to fully predict
the clinical outcome of breast cancer patients with regard
to the heterogenetic biological characteristic of this malig-
nancy. The ER is overexpressed in about 50% breast cancer
patients and could be a prognostic indicator for breast can-
cer patients [21]. However, there is dispute over the defin-
ition of ER positive status nuclear staining by the routinely
used IHC method, which has limited its clinical application
[22-24]. Moreover, not all ER positive breast cancer pa-
tients respond to endocrine therapy; some of the patients
who were sensitive to hormone therapy developed resist-
ance; however, the mechanism is unclear [25,26]. Collect-
ively, these defects limit the application of ER status in
breast cancer management. A close correlation between
PTOV1 expression and ER expression status (r = 0.246, P
= 0.001) suggested that the expression level of PTOV1
might be a useful supplement to breast cancer hormone
therapy decision-making. Thus, PTOV1 may be a useful
marker for determining prognosis and guiding the follow-
up schedule of breast cancer patients.
Our study indicated that PTOV1 might positively regu-
late breast cancer development and progression, and is a
useful indicator of poor prognosis and a prognostic marker
for patient survival. However, the modulation of PTOV1
expression in this malignant tumor and its molecular
mechanisms in breast cancer development and progression
still require further investigation.Conclusions
In this study, we found that PTOV1 overexpression is corre-
lated with breast cancer progression and progressive pheno-
type. Moreover, our data indicated that PTOV1 might be
an independent prognostic marker on the whole group
and subgroup analysis as well. Thus, PTOV1 protein ex-
pression might be a useful marker for stratifying breast
cancer patientsprognosis as well as an effective novel cri-
teria for selection of therapeutic options.
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